Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November

Several healthcare stocks, including Alvotech SA (ALVO), Acadia Healthcare Company (ACHC), and Akebia Therapeutics (AKBA), have become significantly oversold based on RSI following recent negative catalysts. Alvotech's shares plummeted 41% over the past month after receiving an FDA Complete Response Letter for its AVT05 biosimilar application and subsequently revising its 2025 outlook. Acadia Healthcare declined 19% ahead of its upcoming Q3 earnings release, while Akebia Therapeutics dropped 33% in five days, highlighting potential value opportunities for institutional investors monitoring technical indicators and fundamental developments.

Analysis

The healthcare sector is currently presenting several technically oversold opportunities, with Alvotech (ALVO), Acadia Healthcare (ACHC), and Akebia Therapeutics (AKBA) all exhibiting RSI values below 30. Alvotech's shares plummeted 41% over the past month, including a 34.3% drop on Friday to $5.03, following an FDA Complete Response Letter for its AVT05 biosimilar application and a revised 2025 outlook. This regulatory setback, despite management's stated intent to resolve issues, has driven its RSI to an extremely low 18.8, approaching its 52-week low of $4.81.

Acadia Healthcare (ACHC) has seen a 19% decline over the last month, pushing its RSI to 27.9, ahead of its Q3 2025 earnings release scheduled for November 5th. Akebia Therapeutics (AKBA) experienced a 33% drop in its stock over the past five days, closing at $2.12 on Friday, resulting in an RSI of 29.4, attributed to inducement grants under Nasdaq Listing Rule 5635(c)(4). These declines suggest significant short-term negative sentiment impacting these specific equities.

While technical indicators like RSI suggest these stocks are oversold, the underlying catalysts for each company are distinct and fundamental. Alvotech faces regulatory hurdles impacting its product timeline and financial projections, while Acadia's near-term performance hinges on its upcoming earnings report. Akebia's decline, though sharp, is tied to specific corporate actions, indicating a mixed fundamental outlook despite the common technical signal.

Key Decisions for Investors

• Monitor Alvotech's (ALVO) progress on FDA resolution and any revised 2025 outlook, as regulatory clarity will be key to its recovery.
• Await Acadia Healthcare's (ACHC) Q3 2025 earnings report on November 5th for fundamental insights before adjusting positions, given its recent decline.
• Evaluate the long-term implications of Akebia Therapeutics' (AKBA) inducement grants and assess if the sharp sell-off presents a value opportunity.
• Consider these stocks for potential technical rebound plays, but only after a thorough assessment of their respective fundamental catalysts and risk profiles.